“It will also contribute significantly to future growth, with a targeted release platform projected to be another blockbuster treatment with at least $5 billion in annual peak year sales.”

In context

“also want to say a word about Carvicti, our CAR T treatment for multiple myeloma. We have now treated more than 8,500 patients globally, making CARVICTI the most successful CAR T launch ever. With operational sales growing by more than 80% this quarter, we are increasingly confident in Carvicti's $5 billion peak year sales potential. Turning to solid tumors, we were thrilled to receive FDA approval for our bladder cancer treatment, Inlexo, last month. Inlexo highlights what is unique about Johnson & Johnson. Building on our unmatched capabilities in both Innovative Medicine and MedTech, it is the first and only drug-releasing system to provide sustained local delivery of a cancer treatment directly into the bladder. It is transformative for patients, and it is transformative for doctors. It will also contribute significantly to future growth, with a targeted release platform projected to be another blockbuster treatment with at least $5 billion in annual peak year sales. Sourced through an early-stage deal, Inlexo is also an example of our outstanding business development model. In fact, in the last eighteen months alone, we have completed more than 60 deals of this kind. And in lung cancer, we recently published results in the New England Journal of Medicine for Ryberman plus Las Cruze, showing a statistically significant reduction in the risk of death compared to osimertinib. We are now seeing the potential for patients to live significantly longer than anyone thought possible. The combination of DriverBand plus Las Cruze is another of our $5 billion big year sales assets. Next, I want to talk about immunology, where we have been leaders for twenty-five years. From REMICADE to SIMPONI and STELARA to TREMFYA, some of our biggest blockbusters have come fr”